BioMed X announced the launch of a new collaboration with Novo Nordisk (NVO). The new project, entitled “Prolonged Retention of Oral Peptide Formulations in the Gut,” will be hosted at BioMed X in Heidelberg. It aims to develop novel oral formulation technologies that achieve site-specific, prolonged retention of tablets or capsules within the lower small intestine. The key objective is to significantly improve the absorption and bioavailability of peptide-based therapeutics.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVO:
- Hims & Hers Health Stock Falls While GoodRx Rallies on Deal with Novo Nordisk
- Novo Nordisk’s Strategic Focus on Obesity Market and Oral Semaglutide Drives Buy Rating
- Morning News Wrap-Up: Monday’s Biggest Stock Market Stories
- Bullish flow in Novo Nordisk with shares up 4.88%
- Dayforce said in talks to be acquired, Soho House to go private: Morning Buzz